Market Overview

Medtronic Reports Approval of First Artificial Pancreas Device

Related MDT
Medtronic, Inc.: Medtronic Drug-Coated Balloon for Peripheral Artery Disease Tops Standard Balloon Angioplasty in Landmark
UPDATE: Bank Of America Reiterates On Medtronic Post COV Financing
JPM Denies Report of Second Hack Attack (Fox Business)

Medtronic, Inc. (NYSE: MDT) today announced the U.S. Food and Drug Administration (FDA) approval of the MiniMed^® 530G with Enlite^®, a breakthrough, first-generation artificial pancreas system with Threshold Suspend automation for people with diabetes.  Medtronic's system is the first in the United States that can automatically stop insulin delivery when sensor glucose values reach a preset level and when the patient doesn't respond to the Threshold Suspend alarm.  The MiniMed 530G system incorporates the new Enlite sensor, Medtronic's most accurate and comfortable continuous glucose sensor with a 31 percent improvement in overall accuracy from the previous generation.[i]

"The diabetes community has eagerly awaited approval of this system that stops insulin delivery when sensor glucose values fall below a predetermined threshold," said Richard M. Bergenstal, M.D., executive director of the International Diabetes Center at Park Nicollet Health Services in Minneapolis and Clinical Professor for the Department of Medicine at the University of Minnesota. "We are hopeful that advances such as this and improvements in the accuracy of continuous glucose sensors will help people with diabetes strive for better control of their diabetes."

"We're excited to bring yet another important 'first' to the United States. The MiniMed 530G with Enlite can help people gain better control of their diabetes versus multiple daily injections," said Katie Szyman, president of the Diabetes business at Medtronic. "We are committed to advancing closed loop algorithms, continuous glucose monitoring and insulin delivery technologies to bring new artificial pancreas systems to market."

The Enlite sensor delivers better comfort and reliable CGM accuracy.  In addition to the 31 percent improvement in overall accuracy, the Enlite sensor detects up to 93 percent of hypoglycemia episodes when predictive and threshold alerts are on.[ii]  The Enlite sensor is also 69 percent smaller[iii] than the previous Medtronic sensor, to deliver improved comfort in using continuous glucose monitoring.  The new Enlite serter provides a simpler sensor insertion process with a hidden-introducer needle.

The MiniMed 530G system was approved for use by people with diabetes ages 16 and older. Medtronic will conduct a post-approval study including children ages two and older. The Enlite sensor can be worn for six days.

As a condition of approval, in addition to the post-approval study, Medtronic will engage in direct patient follow up and will make certain manufacturing accommodations.  These commitments are consistent with the product approval by the FDA and an accompanying warning letter issued to Medtronic on Sept. 19, 2013.  Medtronic has already addressed many of the observations noted in the warning letter and is committed to resolving the remaining observations as quickly as possible and in accordance with the product approval requirements. Medtronic is committed to providing safe and effective products for people with diabetes.

Medtronic will begin ramping up production immediately to prepare for a launch of the MiniMed 530G in the next several weeks.  In the meantime, customers can find additional product and important safety information at www.medtronicdiabetes.com.

Posted-In: News

 

Related Articles (MDT)

Around the Web, We're Loving...

Get Benzinga's Newsletters